RT Journal Article
SR Electronic
T1 Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.26.22278866
DO 10.1101/2022.10.26.22278866
A1 Aguilar, Ricardo
A1 López-Verges, Sandra
A1 Quintana, Anarellys
A1 Morris, Johanna
A1 Lopez, Lineth
A1 Cooke, Ana
A1 Quiel, Dimas
A1 Buitron, Natalie
A1 Pérez, Yaseikiry
A1 Lobo, Lesbia
A1 Ballesteros, Maura
A1 Pitti, Yaneth
A1 Diaz, Yamilka
A1 Saenz, Lisseth
A1 Franco, Danilo
A1 Castillo, Daniel
A1 Valdespino, Elimelec
A1 Blanco, Isabel
A1 Romero, Emilio
A1 Cubilla-Batista, Idalina
A1 Villarreal, Alcibiades
YR 2022
UL http://medrxiv.org/content/early/2022/10/27/2022.10.26.22278866.abstract
AB At the beginning of the SARS-CoV-2 pandemic, transfusion of COVID-19 convalescent plasma (CCP) was considered as one of the possibilities to help severe patients to overcome COVID-19 disease. The use of CCP has been controversial as its effectiveness depends on many variables from the plasma donor and the COVID-19 patient, for example, time of convalescence or symptoms onset. This was a feasibility study assessing the safety of multiple doses of CCP in mechanically ventilated intubated patients with respiratory failure due to COVID-19. Thirty (30) patients with severe respiratory failure, in ICU, with invasive mechanical ventilation received up to 5 doses of 300 to 600 ml of CP on alternate days (0,2,4,6 and 8) until extubation, futility, or death. Nineteen patients received five doses, seven received four, and four had 2 or 3 doses. On day 28 of follow-up, 57% of patients recovered and were at home and the long-term mortality observed was 27%. The ten severe adverse events reported in the study were unrelated to CCP transfusion. This study suggests that transfusion of multiple doses of convalescent plasma (CP) is safe. This strategy may represent an option to use in new studies, given the potential benefit of CCP transfusions in the early stage of infection in unvaccinated populations and in settings where monoclonal antibodies or antivirals are contraindicated or not available.Summary boxTransfusion of multiple doses (up to 5 doses) of 300-600 ml of convalescent plasma from COVID-19 recovered patients is safe as it does not induce more severe effects than a single dose.Independent of the number of transfused doses, most patients had detectable levels of total and neutralizing antibodies in plasma.Future studies are needed to determine if multiple transfusion doses are more efficient in preventing severity than a single dose.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05595538Funding StatementThis study was partially funded by Sistema Nacional de InvestigacionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee Comite Nacional de Bioetica/Panama gave ethical approval for this work. Protocol code EC-CNBI-2020-04-56 ApprovedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors